Phio Pharmaceuticals Corp is a clinical-stage biopharmaceutical company whose proprietary INTASYL small-interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. Its pipeline programs are PH-762 and PH-894. The group is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. It is committed to discovering and developing cancer treatments for patients by creating new pathways toward a cancer-free future. The Company operates with a single operating segment, the Clinical segment, and all assets are located in the United States.
Last trade$0.7374
Day change-$0.0148 (-1.97%)
Day range$0.691 – $0.771
Volume59,526
Market cap$9M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$8.96M
Price / earnings
—
Price / book
1.04×
Price / sales
—
EV / sales
—
EV / EBITDA
0.11×
Profitability
Earnings per share
-$1.23
Return on assets
-129.65%
Return on equity
-170.21%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
4.19×
Quick ratio
4.19×
Cash ratio
3.93×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$12.4M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for PHIO, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$1.21M
$1.19M
$1.37M
$1.06M
$1.32M
$1.24M
$986K
$689K
Research and development
$3.06M
$3.08M
$2.79M
$1.48M
$1.18M
$1.07M
$886K
$985K
Total operating expenses
$4.27M
$4.27M
$4.17M
$2.53M
$2.51M
$2.31M
$1.87M
$1.67M
Operating income
-$4.27M
-$4.27M
-$4.17M
-$2.53M
-$2.51M
-$2.31M
-$1.87M
-$1.67M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$4.16M
-$4.14M
-$4M
-$2.37M
-$2.39M
-$2.17M
-$1.77M
-$1.63M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$4.16M
-$4.14M
-$4M
-$2.37M
-$2.39M
-$2.17M
-$1.77M
-$1.63M
Net income attributable to common shareholders
-$4.16M
-$4.14M
-$4M
-$2.37M
-$2.39M
-$2.17M
-$1.77M
-$1.63M
EBITDA
-$4.27M
-$4.27M
-$4.17M
-$2.53M
-$2.5M
-$2.31M
-$1.87M
-$1.67M
Basic earnings per share
-$0.36
-$0.36
-$0.34
-$0.25
-$0.44
-$0.45
-$0.41
—
Diluted earnings per share
-$0.36
-$0.36
-$0.34
-$0.25
-$0.44
-$0.45
-$0.41
—
Recent news
Company coverage with links to the original publishers.
The Merkel cell carcinoma market is expected to grow significantly between 2025-2034, driven by rising global incidence, increased awareness, and innovative treatment developments like immunotherapies and targeted therapies.
Phio Pharmaceuticals reported a Q2 2025 net loss of $2.2 million, with its lead candidate PH-762 showing promising early clinical results in cancer therapy. The company's INTASYL platform demonstrated positive safety and efficacy signals in gene-silencing cancer treatments.
The global retinoblastoma treatment market is projected to grow from $1.93 billion in 2023 to $2.03 billion in 2024, driven by factors like increased funding, cancer research, and technological advancements. The market is expected to reach $2.56 billion by 2028, growing at a CAGR of 5.9%.